{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T22:42:48Z","timestamp":1778193768588,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the Shanghai Science and Technology Committee","award":["19411970300"],"award-info":[{"award-number":["19411970300"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s10620-020-06115-7","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T18:03:45Z","timestamp":1580839425000},"page":"3639-3646","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment"],"prefix":"10.1007","volume":"65","author":[{"given":"Laisheng","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingjie","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lou","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Y.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3127-6048","authenticated-orcid":false,"given":"Hong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,4]]},"reference":[{"key":"6115_CR1","first-page":"992","volume":"16","author":"HB El-Serag","year":"2018","unstructured":"El-Serag HB, Kao JY, Kanwal F, et al. Houston consensus conference on testing for Helicobacter pylori infection in the United States. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2018;16:992\u20131002.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"6115_CR2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","volume":"66","author":"P Malfertheiner","year":"2017","unstructured":"Malfertheiner P, Megraud F, O\u2019Morain CA, et al. Management of Helicobacter pylori infection-the maastricht V\/Florence consensus report. Gut. 2017;66:6\u201330.","journal-title":"Gut"},{"key":"6115_CR3","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2016.563","volume":"112","author":"WD Chey","year":"2017","unstructured":"Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112:212\u2013239.","journal-title":"Am J Gastroenterol"},{"key":"6115_CR4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","volume":"151","author":"CA Fallone","year":"2016","unstructured":"Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151:51\u201369.","journal-title":"Gastroenterology"},{"key":"6115_CR5","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.gtc.2015.05.003","volume":"44","author":"DY Graham","year":"2015","unstructured":"Graham DY, Lee SY. How to effectively use bismuth quadruple therapy: the good, the bad, and the ugly. Gastroenterol Clin N Am. 2015;44:537\u2013563.","journal-title":"Gastroenterol Clin N Am"},{"key":"6115_CR6","first-page":"802","volume":"11","author":"X Liang","year":"2013","unstructured":"Liang X, Xu X, Zheng Q, et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2013;11:802\u2013807.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"6115_CR7","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1136\/gutjnl-2015-309900","volume":"64","author":"W Zhang","year":"2015","unstructured":"Zhang W, Chen Q, Liang X, et al. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut. 2015;64:1715\u20131720.","journal-title":"Gut"},{"key":"6115_CR8","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/apt.15273","volume":"49","author":"Q Chen","year":"2019","unstructured":"Chen Q, Long X, Ji Y, et al. Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment. Aliment Pharmacol Ther. 2019;49:1385\u20131394.","journal-title":"Aliment Pharmacol Ther"},{"key":"6115_CR9","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1093\/jac\/dkw220","volume":"71","author":"I Puig","year":"2016","unstructured":"Puig I, Baylina M, Sanchez-Delgado J, et al. Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for Helicobacter pylori first-line treatment. J Antimicrobial Chemother. 2016;71:2740\u20132753.","journal-title":"J Antimicrobial Chemother"},{"key":"6115_CR10","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1128\/AAC.47.10.3138-3144.2003","volume":"47","author":"LM Best","year":"2003","unstructured":"Best LM, Haldane DJM, Keelan M, et al. Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter pylori and correlation between Agar Dilution and E test methods. Antimicrobial Agents Chemother. 2003;47:3138\u20133144.","journal-title":"Antimicrobial Agents Chemother"},{"key":"6115_CR11","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 8.1, 2018. http:\/\/www.eucast.org."},{"key":"6115_CR12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/hel.12242","volume":"21","author":"L Zhou","year":"2016","unstructured":"Zhou L, Zhang J, Song Z, et al. Tailored versus triple plus bismuth or concomitant therapy as Initial Helicobacter pylori treatment: a randomized trial. Helicobacter. 2016;21:91\u201399.","journal-title":"Helicobacter"},{"key":"6115_CR13","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(11)60020-2","volume":"377","author":"P Malfertheiner","year":"2011","unstructured":"Malfertheiner P, Bazzoli F, Delchier J-C, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011;377:905\u2013913.","journal-title":"Lancet"},{"key":"6115_CR14","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1046\/j.1523-5378.2000.00030.x","volume":"5","author":"K Bardhan","year":"2000","unstructured":"Bardhan K, Bayerdorffer E, Veldhuyzen Van Zanten SJ, et al. The HOMER study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection. Helicobacter. 2000;5:196\u2013201.","journal-title":"Helicobacter"},{"key":"6115_CR15","first-page":"743","volume":"86","author":"GD Bell","year":"1993","unstructured":"Bell GD, Powell KU, Burridge SM, et al. Helicobacter pylori eradication: efficacy and side effect profile of a combination of omeprazole, amoxycillin and metronidazole compared with four alternative regimens. Q J Med. 1993;86:743\u2013750.","journal-title":"Q J Med"},{"key":"6115_CR16","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/ajg.2016.443","volume":"111","author":"Q Chen","year":"2016","unstructured":"Chen Q, Zhang W, Fu Q, et al. Rescue therapy for Helicobacter pylori eradication: a randomized non-inferiority trial of amoxicillin or tetracycline in bismuth quadruple therapy. Am J Gastroenterol. 2016;111:1736\u20131742.","journal-title":"Am J Gastroenterol"},{"key":"6115_CR17","first-page":"780 e5\u2013e8","volume":"24","author":"DS Liu","year":"2018","unstructured":"Liu DS, Wang YH, Zeng ZR, et al. Primary antibiotic resistance of Helicobacter pylori in Chinese patients: a multiregion prospective 7-year study. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2018;24:780 e5\u2013e8.","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"6115_CR18","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/jcph.195","volume":"54","author":"T Furuta","year":"2014","unstructured":"Furuta T, Sugimoto M, Yamade M, et al. Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy. J Clin Pharmacol. 2014;54:258\u2013266.","journal-title":"J Clin Pharmacol"},{"key":"6115_CR19","doi-asserted-by":"publisher","first-page":"e12596","DOI":"10.1111\/hel.12596","volume":"24","author":"L Yu","year":"2019","unstructured":"Yu L, Luo L, Long X, et al. High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: a randomized trial. Helicobacter. 2019;24:e12596.","journal-title":"Helicobacter"},{"key":"6115_CR20","doi-asserted-by":"crossref","first-page":"437","DOI":"10.14309\/ajg.0000000000000132","volume":"114","author":"J Yang","year":"2019","unstructured":"Yang J, Zhang Y, Fan L, et al. Eradication efficacy of modified dual therapy compared with bismuth-containing quadruple therapy as a first-line treatment of Helicobacter pylori. Am J Gastroenterol. 2019;114:437\u2013445.","journal-title":"Am J Gastroenterol"},{"key":"6115_CR21","first-page":"335","volume":"35","author":"N Figura","year":"2012","unstructured":"Figura N, Moretti E, Vaglio L, et al. Factors modulating the outcome of treatment for the eradication of Helicobacter pylori infection. New Microbiol. 2012;35:335\u2013340.","journal-title":"New Microbiol"},{"key":"6115_CR22","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/00365520310008674","volume":"39","author":"M Farkkila","year":"2004","unstructured":"Farkkila M, Sarna S, Valtonen V, Sipponen P. Does the \u2018test-and-treat\u2019 strategy work in primary health care for management of uninvestigated dyspepsia? A prospective two-year follow-up study of 1552 patients. Scand J Gastroenterol. 2004;39:327\u2013335.","journal-title":"Scand J Gastroenterol"},{"key":"6115_CR23","first-page":"225","volume":"44","author":"G Mezzi","year":"1998","unstructured":"Mezzi G, Boni F, Corbellini A, et al. Azithromycin versus amoxicillin in triple therapy for the treatment of Helicobacter pylori infection. Minerva Gastroenterol e Dietol. 1998;44:225\u2013229.","journal-title":"Minerva Gastroenterol e Dietol"},{"key":"6115_CR24","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1365-2036.2012.05137.x","volume":"36","author":"J Sanchez-Delgado","year":"2012","unstructured":"Sanchez-Delgado J, Garcia-Iglesias P, Castro-Fernandez M, et al. High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates. Aliment Pharmacol Ther. 2012;36:190\u2013196.","journal-title":"Aliment Pharmacol Ther"},{"key":"6115_CR25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1046\/j.1365-2036.1997.139315000.x","volume":"11","author":"M Strom","year":"1997","unstructured":"Strom M, Sorberg M, Jonsson KA. Immediate repeat course of amoxycillin, metronidazole and omeprazole to eradicate Helicobacter pylori. Aliment Pharmacol Ther. 1997;11:311\u2013316.","journal-title":"Aliment Pharmacol Ther"},{"key":"6115_CR26","first-page":"695","volume":"91","author":"G Bianchi Porro","year":"1996","unstructured":"Bianchi Porro G, Lazzaroni M, Bargiggia S, et al. Omeprazole coupled with two antibiotics for Helicobacter pylori eradication and prevention of ulcer recurrence. Am J Gastroenterol. 1996;91:695\u2013700.","journal-title":"Am J Gastroenterol"},{"key":"6115_CR27","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s00535-010-0220-x","volume":"45","author":"DY Graham","year":"2010","unstructured":"Graham DY, Javed SU, Keihanian S, Abudayyeh S, Opekun AR. Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States. J Gastroenterol. 2010;45:816\u2013820.","journal-title":"J Gastroenterol"},{"key":"6115_CR28","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/gutjnl-2015-311019","volume":"65","author":"MP Dore","year":"2016","unstructured":"Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65:870\u2013878.","journal-title":"Gut"},{"key":"6115_CR29","doi-asserted-by":"crossref","first-page":"e12485","DOI":"10.1111\/hel.12485","volume":"23","author":"X Long","year":"2018","unstructured":"Long X, Chen Q, Yu L, Liang X, Liu W, Lu H. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance. Helicobacter. 2018;23:e12485.","journal-title":"Helicobacter"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06115-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-020-06115-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06115-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:55:05Z","timestamp":1612313705000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-020-06115-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,4]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6115"],"URL":"https:\/\/doi.org\/10.1007\/s10620-020-06115-7","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,4]]},"assertion":[{"value":"15 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Hong Lu is a consultant for Takeda and Astrazeneka, proton pump inhibitors in relation to <i>H. pylori<\/i> infection treatment. Dr. Graham is supported in part by the Office of Research and Development Medical Research Service Department of Veterans Affairs, Public Health Service grant DK56338 which funds the Texas Medical Center Digestive Diseases Center. Dr. Graham is a consultant for RedHill Biopharma and Phathom Pharmaceuticals regarding novel <i>H. pylori<\/i> therapies and has received research support for culture of <i>H. pylori<\/i> and is the PI of an international study of the use of antimycobacterial therapy for Crohn\u2019s disease. Other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the ethics committee of Renji Hospital and with the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}